Are APOL1 risk genotypes associated with cardiovascular disease and stroke in postmenopausal African American women?
In this study of 11 137 participants in the Women’s Health Initiative, high-risk APOL1 genotypes were not associated with coronary heart disease, stroke, and all-cause and cardiovascular mortality. However, high-risk APOL1 genotypes were associated with hospitalized heart failure with preserved ejection fraction, but associations were partly accounted for by baseline kidney function.
This study does not support a relationship among high-risk APOL1 genotypes and cardiovascular disease in postmenopausal women, except for heart failure with preserved ejection fraction, mechanisms of which might include chronic kidney disease.
APOL1 genotypes are associated with kidney diseases in African American individuals and may influence cardiovascular disease and mortality risk, but findings have been inconsistent.
To discern whether high-risk APOL1 genotypes are associated with cardiovascular disease and stroke in postmenopausal African American women, who are at high risk for these outcomes.
Design, Setting, and Participants
The Women's Health Initiative is a prospective cohort that enrolled 161 838 postmenopausal women into clinical trials and an observational study between 1993 and 1998. This study includes 11 137 African American women participants who had a clinical event from enrollment to June 2014. Data analyses were completed from January 2017 to August 2017.
The variants of APOL1 were genotyped or imputed from whole-exome sequencing.
Main Outcomes and Measures
Incident coronary heart disease, stroke and heart failure subtypes, and overall and cause-specific mortality were adjudicated from hospital records and death certificates. Estimated incidence rates were determined for each outcome and hazard ratios (HR) and 95% CIs for the associations of APOL1 groups with outcomes.
The mean (SD) age of participants was 61.7 (7.1) years. Carriers of high-risk APOL1 variants (n = 1370; 12.3%) had higher prevalence of hypertension, use of cholesterol-lowering medications, and reduced estimated glomerular filtration rate (eGFR). After a mean (SD) of 11.0 (3.6) years, carriers of high-risk APOL1 variants had a higher incidence rate of hospitalized heart failure with preserved ejection fraction (HFpEF) than low-risk carriers did but showed no differences for other outcomes. In adjusted models, there was a significant 58% increased hazard of hospitalized HFpEF (HR, 1.58 [95% CI, 1.03-2.41]) among carriers of high-risk APOL1 variants compared with carriers of low-risk APOL1 variants. The association with HFpEF was attenuated (HR = 1.50 [95% CI, 0.98-2.30]) and no longer significant when adjusting for baseline eGFR.
Conclusions and Relevance
Status as a carrier of a high-risk APOL1 genotype was associated with HFpEF hospitalization among postmenopausal women, which is partly accounted for by baseline kidney function. These findings do not support an association of high-risk APOL1 genotypes with coronary heart disease, stroke, or mortality in postmenopausal African American women.
Franceschini N, Kopp JB, Barac A, et al. Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women. JAMA Cardiol. 2018;3(8):712–720. doi:10.1001/jamacardio.2018.1827
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: